Search
for
Sort by
Research 391–420 of 1000+
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Cepharanthine inhibits enterovirus entry by endolysosomal deacidification and exhibits protective activity <i>in vivo</i>
- Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
- Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
- Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
- Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
- Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- Janus kinase inhibitors for alopecia areata: A narrative review
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- The Mechanisms of Anabolic Steroids, Selective Androgen Receptor Modulators and Myostatin Inhibitors
- Pharmacophore and Atom Based 3D QSAR Studies on the Novel 5-Alpha-Reductase Inhibitors
- 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
- Studies on the effect of Sophora flavescens extract on the hair growth stimulation and acne inhibition
- JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- Coordinated inhibition of SOX9 and cell cycle progression by microRNA-200 restricts sebaceous gland fate specification
- Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- ACE2 Inhibits Dermal Regeneration Through Ang II in Tissue Expansion
- Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network
- 51223 A novel human disease model of alopecia areata to evaluate benefit of the DHODH inhibitor farudodstat
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris